Xwell, INC 8-K filings

XWELL, Inc. announced the appointment of Gerard Reid to its Board of Directors and the resignation of Ezra Ernst from the Board, who will continue as CEO.

XWELL, Inc. has entered into a definitive agreement to divest its XpresSpa and XpresTest businesses to Express Wellness Group, LLC for $13 million, aiming to refocus on the national security sector.

XWELL Inc. has amended its prior 8-K filing to formally disclose its board's decision to hold annual "Say-on-Pay" advisory votes, aligning with stockholder preference.

XWELL, Inc. announced fiscal year 2025 financial results, reporting $29.2 million in revenue, reduced operating expenses, and strategic expansions in wellness and biosecurity.

XWELL, Inc. completed a private placement raising $31.3 million through the issuance of Series H Convertible Preferred Stock and Warrants, while simultaneously eliminating its Series G Preferred Stock.

XWELL, Inc. announced a $31.3 million private placement of convertible preferred stock and warrants, with proceeds primarily used to repurchase $9 million in existing debt and for working capital.

XWELL, Inc. stockholders reelected directors, ratified auditors, approved executive compensation, and authorized a reverse stock split and significant share issuance at the 2025 Annual Meeting.

XWELL, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

XWELL, Inc. announced its third quarter 2025 financial results, reporting $7.3 million in revenue and significant cost reductions while expanding its wellness solutions globally.

XWELL, Inc. has amended its Series G Convertible Preferred Stock terms, including reducing the conversion price to $1.00 and adding anti-dilution provisions, following an exchange of preferred stock for senior secured convertible notes.

XWELL, Inc. announced its 2025 Annual Meeting of Stockholders will be held on December 18, 2025, and set new deadlines for shareholder proposals and director nominations.

XWELL, Inc. has exchanged a portion of its Series G Preferred Stock for new senior secured convertible notes and amended existing warrants, aiming to restructure its financial obligations.

XWELL, Inc. announced the cancellation of its 2025 annual meeting of stockholders and the withdrawal of all proposals, with plans to reschedule at a later date.

XWELL, Inc. has adjourned its 2025 Annual Meeting of Stockholders to October 10, 2025, to allow more time for shareholder voting on company proposals.

XWELL, Inc. announced its second quarter 2025 financial results, reporting $7.7 million in revenue and an increased net loss, alongside strategic expansion into new wellness markets.

XWELL, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported non-compliance matter.

XWELL, Inc. has amended its bylaws to lower the required stockholder vote for most matters, excluding director elections, by excluding abstentions and broker non-votes from the vote calculation.

XWELL, Inc. reported its first quarter 2025 financial results, highlighting a focus on expanding its wellness offerings and returning to profitability.

XWELL, Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

XWELL, Inc. dismisses Marcum LLP as its independent registered public accounting firm and engages CBIZ CPAs, effective April 21, 2025.

XWELL, Inc. announces its fiscal year 2024 results, highlighting revenue growth, improved gross margins, and strategic expansion initiatives.

XWELL Inc. stockholders approved an amendment to the company's 2020 Equity Incentive Plan, increasing the number of shares available for grant and the maximum award value for non-employee directors, among other proposals, at a special meeting held on April 10, 2025.

XWELL, Inc. plans to acquire medical spas by the end of 2025, fueled by a recent $4 million private placement, to expand its wellness and beauty offerings.

XWELL Inc. has announced a three-year extension of its Traveler-based Genomic Surveillance Program with the Centers for Disease Control and Prevention (CDC).

XWELL, Inc. has successfully closed a $4 million private placement, issuing convertible preferred stock and warrants to support its growth strategy.

XWELL, Inc. has announced the appointment of Thomas Ian Brown as its new Chief Financial Officer, along with other key leadership changes, to support the company's strategic growth and business objectives.

XWELL, Inc. is unifying its wellness services under a single brand and expanding its reach with new out-of-airport locations, aiming to capitalize on the rapidly growing wellness market.

XWELL, Inc. announced a 13% revenue increase for the third quarter of 2024 and a 16% increase for the nine-month period, alongside significant reductions in operating expenses.

XWELL, Inc. held its 2024 Annual Meeting of Stockholders, where directors were re-elected, the appointment of the accounting firm was ratified, executive compensation was approved, and a tax benefits preservation plan was ratified.

XWELL, Inc. has appointed Ezra T. Ernst as its new President and Chief Executive Officer, succeeding Scott R. Milford, who will transition to a consulting role.